The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 | Issue Briefs Featured Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable?April 2, 2020 | Journal Article Pharmacy Benefit Managers: Practices, Controversies, and What Lies AheadMarch 26, 2019 | Issue Briefs Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare BeneficiariesJuly 1, 2019 | Journal Article Reducing Wasteful Spending in Employers’ Pharmacy Benefit PlansAugust 30, 2019 | Issue Briefs Prescription drugs accounted for 17 percent of total U.S. health care spending — or about $457 billion — in 2015. And that share is expected to rise over the next decade as drug costs outpace those of all other health care services. Policymakers need unbiased information and insight into what drives pharmaceutical prices and spending so they can develop feasible, effective policy solutions. Leave this field blank Our Experts Lovisa GustafssonVice President, Controlling Health Care Costs Media Mention read on: CNBCJanuary 14, 2019 Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement FDA Actions on Drug Pricing A Timeline Explore Timeline The Latest in Prescription Drugs Narrow by: Author Anderson, ChloeAnderson, GerardAnderson, Kelly E.Baumgartner, Jesse C.Beutel, SophieBishop, ShawnBlumenthal, DavidBrooks-LaSure, ChiquitaCall, AdrienneColeman, AkeiisaCollins, Sara R.Conti, RenaCorr, BillDavis, KarenDoty, Michelle M.Duong, SophiaDusetzina, Stacie B.Ex, PatriciaFowler, ElizabethFrank, Richard G.Fry, CarrieGabel, Jon R.Ginsburg, Paul B.Glied, Sherry A.Green, Matthew Gunja, Munira Z.Gustafsson, LovisaGuyer, JocelynHorvath, JaneJha, Ashish K.Jost, Timothy S.Kang, So YeonKenyatta, KahaariKeohane, Laura M.Kesselheim, Aaron S.LaRosa, JoshLieberman, Steven M.Llamas, AlyssaMann, CindyMartin, KristiMcDonald, RuthMorgan, StevenMoulds, DonaldNuzum, RachelOran, RebeccaOsborn, RobinPanteli, DimitraPapanicolas, IreneParasrampuria, SonalPatel, KavitaPaxton, IsabelRamsay, ChristinaRiley, TrishRobinson, James C.Rodwin, Marc A.Rother, JohnSarnak, Dana O.Schneider, Eric C.Schoen, CathySeeley, ElizabethSeervai, ShanoorSen, Aditi P.Shah, ArnavSharp, JeremySquires, DavidStromberg, SamVela, LaurenWaxman, HenryWhitmore, HeidiWillink, AmberWoskie, Liana R.Wynne, BillyZhu, Benjamin Date Last 7 daysLast 30 daysLast 6 monthsPast yearOver a year agoOver 2 years agoOver 3 years agoOver 4 years agoOver 5 years ago Type Fund ReportsTo The PointIssue BriefsExplainerInfographicJournal ArticlePodcastOther Publication View By: Card View Card View List View Apply Leave this field blank Publication Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing February 4, 2019 By James C. Robinson, Dimitra Panteli, Patricia Ex To the Point The FDA’s Drug Pricing Strategy: What’s New? January 28, 2019 By Henry Waxman, Bill Corr, Kristi Martin, Jeremy Sharp, Sophia Duong To the Point Proposed Changes to Medicare Part D Would Benefit Drug Manufacturers More Than Beneficiaries January 2, 2019 By Shawn Bishop To the Point Old Lessons for the New Medicare Part B Drug Payment Model November 26, 2018 By Kristi Martin, Jeremy Sharp Publication What’s Driving Prescription Drug Prices in the U.S.? November 14, 2018 By Steven Morgan To the Point Medicaid Provisions in the SUPPORT Act: An Important Step Forward in the Opioid Epidemic, but the Road Ahead Is Long November 13, 2018 By Cindy Mann, Jocelyn Guyer To the Point The Midterm Election Results Have Big Implications for Health Care November 7, 2018 By Donald Moulds, Sara R. Collins, Rachel Nuzum, Akeiisa Coleman, Shawn Bishop To the Point HHS Proposes to Link Medicare Part B Payment for Prescription Drugs to International Price October 26, 2018 By Shawn Bishop, Christina Ramsay, Lovisa Gustafsson, Kristi Martin To the Point Congress Is Making Quiet Progress on Drug Costs September 21, 2018 By Kristi Martin, Jeremy Sharp To the Point A Closer Look at the Senate’s Bipartisan Legislation Targeting the Opioid Epidemic September 13, 2018 By Rachel Nuzum Publication Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.? September 10, 2018 By James C. Robinson To the Point Three Essentials for Negotiating Lower Drug Prices August 22, 2018 By David Blumenthal, Shanoor Seervai, Shawn Bishop Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »
